WisdomTree Launches Emerging Markets Consumer Growth Fund

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
WisdomTree Launches Emerging Markets Consumer Growth Fund (EMCG)

NEW YORK, Sept. 27, 2013 (GLOBE NEWSWIRE) -- WisdomTree (Nasdaq: WETF ), an exchange-traded fund ("ETF") sponsor and asset manager, today announced the launch of the WisdomTree Emerging Markets Consumer Growth Fund (Nasdaq: EMCG ) on the NASDAQ Stock Market. EMCG is designed to provide exposure to consumer growth stocks in the emerging markets and has an expense ratio of 0.63%.

Jeremy Schwartz, WisdomTree Director of Research, said, "One of the major themes we believe will drive much of the global economy over the coming years is the potential growth from the emerging market consumers. Despite short-term noise in the markets this year, the strong underlying fundamentals of emerging markets are demographic in nature (larger and younger populations compared to the developed world) and have not deteriorated, nor do they shift much year-to-year."

Combining Broadly Diversified Approach to Reflect Growing EM Consumption with Valuation Sensitivity

Mr. Schwartz continued, "Despite the importance of this theme, there are few options to access it beyond concentrated 'consumer' sector strategies which lack a mechanism to address the potential for elevated valuations, given high expectations for growth."

"We have designed EMCG to provide exposure to broad cross sections of the markets, beyond one or two sectors, in companies we believe are positioned to benefit from the growth of emerging market consumption. Additionally, we marry this stock selection with a rigorous, rules based framework to incorporate a sensitivity to valuations in our exposures," Mr. Schwartz concluded.

The WisdomTree Emerging Markets Consumer Growth Fund (EMCG) seeks to offer:

  • A diversified basket of earnings-weighted securities, generating at least 60% of revenue from the emerging markets and no more than 25% of revenue from the U.S., Europe or Japan.
  • Exposure to stocks most sensitive to growth in local economies comprised of both consumer sector stocks, 1 and non-consumer sector stocks with the best combined rank of growth, quality and valuation factors.
  • At annual index rebalance, single stock cap of 5%, country cap of 25% 2 , 60% allocation to specific consumer sectors and 40% allocation to other sectors.
 __________________
1 Consumer Sectors: Consumer Staples and Consumer Discretionary.
2 Between annual rebalances, single stock weights and sector weights may fluctuate above the 5% and 25% marks, respectively, due to market movement.

Investors should carefully consider the investment objectives, risks, charges and expenses of the Funds before investing. To obtain a prospectus containing this and other important information, call 866-909-9473 or visit wisdomtree.com. Read the prospectus carefully before investing.

Diversification does not eliminate the risk of experiencing investment losses.
This Fund is new and has limited operating history.

There are risks associated with investing, including possible loss of principal.  Foreign investing involves special risks, such as risk of loss from currency fluctuation or political or economic uncertainty.  Funds focusing on a single sector and/or smaller companies generally experience greater price volatility.  Investments in emerging, offshore or frontier markets are generally less liquid and less efficient than investments in developed markets and are subject to additional risks, such as risks of adverse governmental regulation, intervention and political developments.  Due to the investment strategy of this Fund it may make higher capital gain distributions than other ETFs.  Please read the Fund's prospectus for specific details regarding the Fund's risk profile.

WisdomTree Funds are distributed by ALPS Distributors, Inc. 
Jeremy Schwartz is a registered representative of ALPS Distributors, Inc.
WIS005733 (9/2014)

About WisdomTree

WisdomTree® is a New York-based exchange-traded fund ("ETF") sponsor and asset manager. WisdomTree currently offers 53 ETFs across Equities, Fixed Income, Currency Income and Alternatives asset classes. WisdomTree also licenses its indexes to third parties for proprietary products and promotes the use of WisdomTree ETFs in 401(k) plans. WisdomTree currently has approximately $31.5 billion in ETF assets under management. For more information, please visit www.wisdomtree.com or follow us on Twitter @WisdomTreeETFs .

WisdomTree is the marketing name for WisdomTree Investments, Inc. and its wholly owned subsidiaries WisdomTree Asset Management, Inc. and WisdomTree Retirement Services, Inc. WisdomTree Asset Management, Inc. is a registered investment advisor and is the investment advisor to the WisdomTree Trust and the WisdomTree ETFs. The WisdomTree Trust is a registered open-end investment company. Each WisdomTree ETF is a series of the WisdomTree Trust. WisdomTree Retirement Services, Inc. supports the use of the WisdomTree ETFs in retirement plans by financial professionals.  

WisdomTree Investments, Inc. Stuart Bell / Jessica Zaloom +1.917.267.3702 / +1.917.267.3735 /

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 11

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 7

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 7

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 11

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 4

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 10

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 6

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 10

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 5

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Bonati Spine Institute Celebrates 42 Years of Impact

Updated Category News Views 8

Legacy of Innovation: Bonati's Distinct Contribution Bonati Spine Institute isn't about resting on laurels; it's about changing the game of spine surgery. When Dr. Alfred Bonati rolled up his sleeves back in 1984 and decided 'enough is enough' with open surgeries and long recovery roads, he wasn't just making noise. He was setting the stage for something...

Continue Reading
Understanding Recent Options Movements for Royal Caribbean

Updated Category News Views 154

Overview of Recent Options Activities for Royal Caribbean Group Recently, there's been some fascinating activity within the options market for Royal Caribbean Group, also known by its ticker symbol RCL. Known for its vast fleet and innovative cruise experiences, Royal Caribbean has made headlines in the financial market due to the increasingly bearish sentiment...

Continue Reading
Sandstorm Gold Sees Historic Growth in Recent Quarter

Updated Category News Views 126

Overview of Sandstorm Gold Ltd. Sandstorm Gold Ltd. is an innovative player in the precious metals sector, known for its unique business model. This company specializes in providing upfront financing to mining operations, allowing them to grow while securing a portion of the mine's production for the life of its operation. Its portfolio consists of approximately 230...

Continue Reading
Woodlands Financial Services Declares Third Quarter Dividend

Updated Category News Views 87

Woodlands Financial Services Company Reports Dividend Announcement In a recent development that is sure to please its investors, Woodlands Financial Services Company (NASDAQ: WDFN) has announced a substantial cash dividend for the third quarter. This decision reflects the company's commitment to returning value to its shareholders, marking a positive step forward in its...

Continue Reading
Broadcom Stock Under Pressure: Insights and Future Outlook

Updated Category News Views 92

Current Trends Affecting Broadcom Stock Broadcom Inc. (NASDAQ: AVGO) has recently experienced a downturn in share prices. As of the latest update, Broadcom shares are trading lower, continuing a downward trend following a cautious outlook issued by the company in the prior week. This decline has raised questions among investors and analysts alike about the future...

Continue Reading